| [1] | Rueda LJ, Motta A, Pabón JG, et al. Epidemiology of rosacea in Colombia[J]. Int J Dermatol, 2017,56(5):510⁃513. doi: 10. 1111/ijd.13491. | 
																													
																						| [2] | Johnston SA, Krasuska M, Millings A, et al. Experiences of rosacea and its treatment: an interpretative phenomenological analysis[J]. Br J Dermatol, 2018,178(1):154⁃160. doi: 10.1111/bjd.15780. | 
																													
																						| [3] | Tan J, Steinhoff M, Berg M, et al. Shortcomings in rosacea diagnosis and classification[J]. Br J Dermatol, 2017,176(1):197⁃199. doi: 10.1111/bjd.14819. | 
																													
																						| [4] | Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel[J]. Br J Dermatol, 2017,176(2):431⁃438. doi: 10.1111/bjd.15122. | 
																													
																						| [5] | Forero Molina MA, Garcia E, Gonzalez⁃Devia D, et al. A 17⁃year⁃old male with a small bowel neuroendocrine tumor: flushing differential diagnosis[J]. World Allergy Organ J, 2017,10(1):30. doi: 10.1186/s40413⁃017⁃0161⁃4. | 
																													
																						| [6] | Sadeghian A, Rouhana H, Oswald⁃Stumpf B, et al. Etiologies and management of cutaneous flushing: nonmalignant causes[J]. J Am Acad Dermatol, 2017,77(3):391⁃402. doi: 10.1016/j.jaad.2016.12.031. | 
																													
																						| [7] | Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis[J]. J Clin Oncol, 2009,27(17):2831⁃2837. doi: 10. 1200/JCO.2008.19.6253. | 
																													
																						| [8] | Haber R, El Gemayel M. Comorbidities in rosacea: a systematic review and update[J]. J Am Acad Dermatol, 2018,78(4):786⁃792.e8. doi: 10.1016/j.jaad.2017.09.016. | 
																													
																						| [9] | Egeberg A, Ashina M, Gaist D, et al. Prevalence and risk of migraine in patients with rosacea: a population⁃based cohort study[J]. J Am Acad Dermatol, 2017,76(3):454⁃458. doi: 10. 1016/j.jaad.2016.08.055. | 
																													
																						| [10] | Egeberg A, Hansen PR, Gislason GH, et al. Patients with rosacea have increased risk of depression and anxiety disorders: a danish nationwide cohort study[J]. Dermatology, 2016,232(2):208⁃213. doi: 10.1159/000444082. | 
																													
																						| [11] | Scharschmidt TC, Yost JM, Truong SV, et al. Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment[J]. Arch Dermatol, 2011,147(1):123⁃126. doi: 10.1001/archdermatol.2010.413. | 
																													
																						| [12] | Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel[J]. Br J Dermatol, 2017,176(2):465⁃471. doi: 10.1111/bjd.15173. | 
																													
																						| [13] | Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea[J]. J Eur Acad Dermatol Venereol, 2017,31(11):1775⁃1791. doi: 10.1111/jdv.14349. | 
																													
																						| [14] | Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase Ⅲ clinical trials evaluating anti⁃inflammatory dose doxycycline (40⁃mg doxycycline, USP capsules) administered once daily for treatment of rosacea[J]. J Am Acad Dermatol, 2007,56(5):791⁃802. doi: 10.1016/j.jaad.2006.11.021. | 
																													
																						| [15] | Park JM, Mun JH, Song M, et al. Propranolol, doxycycline and combination therapy for the treatment of rosacea[J]. J Dermatol, 2015,42(1):64⁃69. doi: 10.1111/1346⁃8138.12687. | 
																													
																						| [16] | van der Linden M, van Ratingen AR, van Rappard DC, et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single⁃blinded, noninferiority trial, comparing efficacy and safety[J]. Br J Dermatol, 2017,176(6):1465⁃1474. doi: 10.1111/bjd.15155. | 
																													
																						| [17] | Two AM. Minocycline as an alternative to doxycycline in the treatment of rosacea[J]. Br J Dermatol, 2017,176(6):1426. doi: 10.1111/bjd.15514. | 
																													
																						| [18] | Uslu M, Şavk E, Karaman G, et al. Rosacea treatment with intermediate⁃dose isotretinoin: follow⁃up with erythema and sebum measurements[J]. Acta Derm Venereol, 2012,92(1):73⁃77. doi: 10.2340/00015555⁃1204. | 
																													
																						| [19] | van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments[J]. Br J Dermatol, 2019,181(1):65⁃79. doi: 10.1111/bjd.17590. | 
																													
																						| [20] | Asai Y, Tan J, Baibergenova A, et al. Canadian clinical practice guidelines for rosacea[J]. J Cutan Med Surg, 2016,20(5):432⁃445. doi: 10.1177/1203475416650427. | 
																													
																						| [21] | Two AM, Wu W, Gallo RL, et al. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors[J]. J Am Acad Dermatol, 2015,72(5):749⁃760. doi: 10.1016/j.jaad. 2014.08.028. | 
																													
																						| [22] | Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation[J]. J Investig Dermatol Symp Proc, 2011,15(1):33⁃39. doi: 10.1038/jidsymp.2011.8. | 
																													
																						| [23] | Gilman SE, Trinh NH, Smoller JW, et al. Psychosocial stressors and the prognosis of major depression: a test of Axis IV[J]. Psychol Med, 2013,43(2):303⁃316. doi: 10.1017/S0033291712 001080. | 
																													
																						| [24] | Weber MD, Godbout JP, Sheridan JF. Repeated social defeat, neuroinflammation, and behavior: monocytes carry the signal[J]. Neuropsychopharmacology, 2017,42(1):46⁃61. doi: 10.1038/ npp.2016.102. | 
																													
																						| [25] | Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases(review)[J]. Mol Med Rep, 2016,13(4):3391⁃3396. doi: 10.3892/mmr.2016.4948. | 
																													
																						| [26] | Vidal Yucha SE, Tamamoto KA, Kaplan DL. The importance of the neuro⁃immuno⁃cutaneous system on human skin equivalent design[J]. Cell Prolif, 2019,52(6):e12677. doi: 10.1111/cpr. 12677. | 
																													
																						| [27] | Hinwood M, Tynan RJ, Charnley JL, et al. Chronic stress induced remodeling of the prefrontal cortex: structural re⁃organization of microglia and the inhibitory effect of minocycline[J]. Cereb Cortex, 2013,23(8):1784⁃1797. doi: 10.1093/cercor/bhs151. | 
																													
																						| [28] | Pietschke K, Schaller M. Long⁃term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol[J]. J Dermatolog Treat, 2018,29(3):310⁃313. doi: 10.1080/09546634.2017.1360991. | 
																													
																						| [29] | Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β⁃adrenergic blocker[J]. J Am Acad Dermatol, 2012,67(3):491⁃493. doi: 10.1016/j.jaad.2012.04.017. | 
																													
																						| [30] | Weihe E, Schütz B, Hartschuh W, et al. Coexpression of cholinergic and noradrenergic phenotypes in human and nonhuman autonomic nervous system[J]. J Comp Neurol, 2005,492(3):370⁃379. doi: 10.1002/cne.20745. |